Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles

Open Access

Original Article

Pak J Nucl Med. 2015; 5(1): 51-57

Frequency of cisplatin-induced severe renal injury in patients with solid tumours on renal scintigraphy

Muhammad Inamullah, Mujahid Khalid Ali, Syed Mehdi Raza, Ehsan Mehmood, Zeeshan Ahmad Alvi.

Objective: Cisplatin is an effective chemotherapeutic drug for the treatment of solid tumours. However, its nephrotoxic side effects limit its optimal use and renal scintigraphy may be a reliable diagnostic tool for detecting, evaluating, and quantifying any cisplatin-induced nephrotoxicity. This crosssectional retrospective study was designed to determine the frequency of cisplatin-induced severe renal injury by radionuclide renal scintigraphy in patients with solid tumours undergoing chemotherapy with cisplatin-based regimens. The at the Nuclear Medical Centre, Armed Forces Institute of Pathology (AFIP). Methods: 62 patients (48 male, 14 female) who were candidates for cisplatin-based chemotherapy and had normal renal function as evidenced by normal serum urea and creatinine levels and a normal value of ageadjusted GFR on 99mTc-99m-DTPA renal scintigraphy as per guidelines of National kidney Foundation, were subjected to post chemotherapy 99mTc-DTPA renal scintigraphy within 02 weeks of completion of 06 cycles cisplatin-based chemotherapy. Results: The frequency of severe renal injury was calculated as 2/62 (3.2%) as determined by 99mTc-DTPA scintigraphy after completion of 6 cycles of chemotherapy Conclusion: 3.2% of all patients developed severe renal injury at the completion of 6 cycles of cisplatin based chemotherapeutic regimen. This included patients with severe renal injury (GFR 15-29 ml/min) as well as patients with severe renal injury leading to absolute renal failure (GFR < 15 ml/min).

Similar Articles

Full-text options

Latest Statistics about COVID-19
• pubstat.org

Add your Article(s) to Indexes
• citeindex.org

Covid-19 Trends and Statistics
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.

ScopeMed Web Sites